16240-00-9

Usage

Uses

Used in Pharmaceutical Industry:
(2Z)-3-(2-methylphenyl)-2-[(2-methylphenyl)imino]-1,3-thiazolidin-4-one is used as a pharmaceutical agent for its potential anti-inflammatory properties, offering a therapeutic option for treating inflammation-related conditions.
(2Z)-3-(2-methylphenyl)-2-[(2-methylphenyl)imino]-1,3-thiazolidin-4-one is used as an anticancer agent, targeting various types of cancer cells and potentially serving as a novel therapeutic approach in oncology.
(2Z)-3-(2-methylphenyl)-2-[(2-methylphenyl)imino]-1,3-thiazolidin-4-one is used as an antimicrobial agent, providing an alternative for combating microbial infections and contributing to the development of new antibiotics.
Used in Medicinal Chemistry Research:
(2Z)-3-(2-methylphenyl)-2-[(2-methylphenyl)imino]-1,3-thiazolidin-4-one is used as a research compound for the development of new drugs, given its promising pharmacological properties and potential applications in various therapeutic areas.
(2Z)-3-(2-methylphenyl)-2-[(2-methylphenyl)imino]-1,3-thiazolidin-4-one is used as a starting material for the synthesis of thiazolidin-4-one derivatives, which are being investigated for their antioxidant and antidiabetic properties, expanding the scope of its potential applications.

Upstream product

• 19801-31-1 S-ethyl-N,N'-di-o-tolyl-isothiourea 
• 68-11-1 mercaptoacetic acid 
• 65252-02-0 S-methyl-N,N'-di-o-tolyl-isothiourea 
• 22695-18-7 N,N-di-o-tolylthiourea 
• 79-11-8 chloroacetic acid 
• 137-97-3 N,N'-di(o-tolyl)thiourea 
• 95-53-4 o-toluidine 
• 105-39-5 chloroacetic acid ethyl ester 
• 79-08-3 bromoacetic acid 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 617-07-2 N,N'-bis(2-methylphenyl)urea 
• 68-11-1 mercaptoacetic acid 
• 102754-25-6 5-benzylidene-2-(o-tolyl)imino-3-(o-tolyl)-thiazolidin-4-one 
• 304894-29-9 C₂₄H₂₀N₂O₂S 
• 1280723-04-7 4-(5-((4-oxo-3-(2-methylphenyl)-2-(2-methylphenylimino)thiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid 
• 1228044-60-7 3-(5-((4-oxo-3-(2-methylphenyl)-2-(2-methylphenylimino)thiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid 
• 16240-02-1 3-o-tolylthiazolidine-2,4-dione 
• 114553-01-4 5-(4-dimethylamino-benzylidene)-3-o-tolyl-2-o-tolylimino-thiazolidin-4-one 
• 102704-49-4 5-furfurylidene-3-o-tolyl-2-o-tolylimino-thiazolidin-4-one 

Relevant academic research and scientific papers

Novel non-peptidic small molecule inhibitors of secreted aspartic protease 2 (SAP2) for the treatment of resistant fungal infections

Targeting secreted aspartic protease 2 (SAP2), a kind of virulence factor, represents a new strategy for antifungal drug discovery. In this report, the first-generation of small molecule SAP2 inhibitors was rationally designed and optimized using a structure-based approach. In particular, inhibitor 23h was highly potent and selective and showed good antifungal potency for the treatment of resistant Candida albicans infections.

Thiazolidione derivatives as novel antibiofilm agents: Design, synthesis, biological evaluation, and structure-activity relationships

Rational designed novel thiazolidiones were synthesized and evaluated for antibiofilm activity. The active derivatives were not only potent inhibitors of Staphylococcus epidermidis biofilm growth but also efficient antibacterial agents. 3f showed 4-fold higher activity (6.25 μM) in the biofilms dispersal assay and significantly higher antibacterial activity (MIC 3.125 μM) in comparison to the 3-(5-((6- (ethoxycarbonyl)-5-(benzo[1,3]dioxol-5-yl)-3-oxo-7- phenyl- thiazolo[3,2-a]pyrimidin-2(5H)-ylidene)methyl)furan-2-yl)benzoic acid (1).

Design, synthesis, and antibiofilm activity of 2-arylimino-3-aryl-thiazolidine-4-ones

A series of novel 2-arylimino-3-aryl-thiazolidine-4-ones was designed, synthesized and tested for in vitro antibiofilm activity against Staphylococcus epidermidis. Among them tested, some compounds with carboxylic acid groups showed good antibiofilm activity. The antibiofilm concentration of 1x was 6.25 μM. The structure-activity relationships revealed that incorporation of 2-phenylfuran moiety could greatly enhance antibiofilm activity of thiazolidine-4-one.

Axially chiral 2-arylimino-3-aryl-thiazolidine-4-one derivatives: Enantiomeric separation and determination of racemization barriers by chiral HPLC

Axially chiral 2-arylimino-3-aryl-thiazolidine-4-ones have been synthesized as racemic mixtures, and each mixture with the exception of 2-(o-chlorophenyl)imino-3-(o-chlorophenyl)-thiazolidine-4-one has been converted to the corresponding 5-benzylidene-2-a